赞助商

以下为支持 ChinaBio® 创业投资论坛的赞助机构和合作伙伴。我们诚挚地感谢所有这些一流机构和单位对本届论坛的大力协助和支持。

金牌赞助商

 

Suzhou Industrial Park (SIP) Bio Bay is located in the southwest of SIP Dushu lake high education town. Suzhou Industrial Park, the biggest cooperation program between China and Singapore, is committed to develop into a high-tech industrial park with international competitiveness and a modern, international garden-like township. SIP Bio Bay plays a key role as the innovation base for Suzhou Industrial Park to cultivate biotechnology industry and also an innovation platform for the booming of biotechnology and nanotechnology development of both Suzhou city and China. www.biobay.com.cn/en/index.html

 

 

Broad & Bright is a full service Chinese law firm with international perspectives, providing a broad range of specialized legal services in multiple practice areas for domestic and international clients, with particular expertise and outstanding achievements in cross-border business transactions. Our Chinese and international educated lawyers have long term practice experience at Chinese and international law firms. www.broadbright.com

 

 

Foley is a highly regarded, international law firm providing client-focused, industry-specific services that result in high-value legal counsel for our clients. Our practice areas encompass the full range of corporate legal services. With an office located in Shanghai, the attorneys of Foley’s China Practice are well positioned to assist U.S., Asian, and European clients with the complex matters that arise when doing business in or related to Greater China. From IP procurement and technology transfer to M&A due diligence, count on Foley’s experience and our cultural and business connections in China to help you stake you claim. www.foley.com

 

 

Life Technologies Corporation (NASDAQ: LIFE) is a global biotechnology tools company dedicated to improving the human condition. Our systems, consumables and services enable researchers to accelerate scientific exploration, driving to discoveries and developments that make life even better. Life Technologies customers do their work across the biological spectrum, working to advance personalized medicine, regenerative science, molecular diagnostics, agricultural and environmental research, and 21st century forensics. Life Technologies had sales of more than $3 billion in 2008, employs approximately 9,500 people, has a presence in more than 100 countries, and possesses a rapidly growing intellectual property estate of approximately 3,600 patents and exclusive licenses. Life Technologies was created by the combination of Invitrogen Corporation and Applied Biosystems Inc. For more information on how we are making a difference please visit our website: www.lifetechnologies.com

 

 

Morrison & Foerster’s Life Sciences Practice is comprised of more than 160 attorneys dedicated to serving life sciences companies, research institutions, and the venture capital funds and investments banks that finance them. Morrison & Foerster is a global law firm offering services in corporate finance, mergers & acquisitions, patent strategy and prosecution, collaborations and licensing agreements, trade secret litigation and counseling, employment and labor, and commercial, intellectual property and securities litigation. With offices in Shanghai, Beijing, and Hong Kong, as well as Tokyo, Europe and the United States, we are uniquely positioned to assist life sciences entities around the world. www.mofo.com 

 

 

Mingly China Growth Fund is a private equity fund formed in 2006 to make critical growth and expansion stage investments in China. The Fund Management Team and its Advisors include a collaboration of successful and experienced U.S. and Chinese investment professionals Demonstrated ability to identify sector leaders early and get closely engaged with founders Deep and growing pipeline with active processes to monitor companies, Hands-on operating experience to help transform companies, Global network of contacts to assist with technology, sales and marketing and management expertise, and Both Foreign Currency Fund and RMB Fund to meet the funding needs of various companies. www.mcgf.com.cn

 

Pfizer has been operating in China since the early 1980's committed to improving the health of the Chinese people and contributing to China's overall prosperity. Pfizer has built on this legacy by introducing innovative, relevant medicines and investing in doctor and patient educational programs. Furthermore, Pfizer contributes to China's scientific and medical development by including China in our global R&D projects. In recognition of the highly-skilled and talented scientists in China, Pfizer established its China Research and Development Center in Shanghai in 2005. The center is staffed with more than 200 Pfizer colleagues supporting various aspects of Pfizer's global R&D efforts. www.pfizer.com

 

The Balloch Group ("TBG") was established in 2001 by Howard Balloch (Canada's ambassador to China from 1996 to 2001). TBG has since grown from a market-entry consultancy working with North American clients in China to a leading advisory and merchant banking firm serving both domestic Chinese companies and multinational corporations. TBG was ranked as the number one boutique investment bank in China by ChinaVenture in 2008. TBG's professionals are located in Beijing, New York, Shanghai, Hong Kong, Wuhan and Hangzhou serving and investing alongside our clients in mergers and acquisitions, capital markets and direct investment transactions. www.ballochgroup.com

银牌赞助商

OrbiMed is the world’s largest healthcare and life sciences-dedicated investment firm, with approximately $5 billion in assets under management. Since inception of its private equity investment activities in 1993, OrbiMed has successfully invested in over 100 private companies across a wide range of therapeutic categories and stages of development. OrbiMed’s investment team includes over 30 experienced professionals with backgrounds in science, medicine, industry, finance and law. OrbiMed launched the first pan-Asia healthcare and life sciences-dedicated venture capital fund in 2008, with close to $200 million in commitments. OrbiMed maintains offices in New York City, Shanghai, Mumbai and San Francisco. www.OrbiMed.com

官方合作伙伴

BayHelix is an organization of leaders of Chinese origin in the global life sciences and healthcare community. We aspire to shape the growth of the life sciences and healthcare industry around the Pacific Rim and beyond, foster and create business opportunities, supply and nurture the leaders for the community, and network and share information and experience. BayHelix is a non-profit organization and its membership is by-invitation-only. www.bayhelix.org

BioCentury Publications, Inc. provides essential biopharma industry intelligence from five offices in the U.S. and Europe. For more than 16 years, a global audience of biotech and pharmaceutical executives and investors has benefited from BioCentury's deep knowledge, data-driven analysis, independent perspective and trustworthy content available through the company's publications, data products and collaborative industry conferences in the U.S., Europe and Asia. BioCentury's titles include the flagship BioCentury, the Bernstein Report on BioBusiness; its SciBX: Science-Business eXchange translational science joint publishing venture with Nature Publishing Group; and its BioCentury Extra online daily newspaper. These timely journals are backed by BCIQ: BioCentury Online Intelligence,an online business intelligence resource. www.biocentury.com

Business Wire is a trusted partner to thousands of Health, Medical, Biotech and Pharmaceutical companies and organizations throughout the world, delivering more corporate news releases from more sources to more destinations than any other service.

Business Wire's news wire circuits enable you to target your news to select audiences based on your geographic and industry market needs. Business Wire is the only commercial news wire with full-carriage access to all of the world's leading news agencies, including the Associated Press, Agence France-Presse, Dow Jones, Reuters, Jiji Press, Interfax and more. We can send your news to virtually any media market in the world with distribution to more than 150 countries in dozens of local languages. From delivery to audiences in a single city to comprehensive worldwide coverage including translations, Business Wire offers you an easy, one-stop solution.  www.businesswire.com

Essinova Life Science TV is an Internet TV channel and community for life sciences, biopharma, medical devices and healthcare services industries. We produce and publish executive interviews, corporate videos, investor pitches, product demos, science and technology visualization, event videos and other multimedia content serving companies and organizations in business for health. Our program brings fresh perspectives, candid insights, unique stories and practical expertise to our viewers. Our creative and broadcast-quality productions showcase innovative ideas, technologies, products and methodologies for our clients more compellingly than any conventional media. We help our clients and members deliver their messages to their desired audience efficiently and cost-effectively, utilizing the power of rich and social media, and leveraging our growing network of partnerships.  www.essinova.com

goBalto is a dedicated online drug development partnering site for the pharmaceutical and drug manufacturing industry. Users can identify, evaluate, and manage drug-development partners from around the world. Incorporating the latest in Web 2.0 technologies, goBalto’s platform enables users to distinguish their offerings by adding logos, images, videos, customer testimonials and post referrals from members. More than 7,000 service providers are currently listed. www.goBalto.com

Since 1969, Kidder Mathews has built a reputation of integrity and is known for focusing on delivering results that meet and often exceed client expectations. Over the years, Kidder Mathews has grown from a niche company to the acknowledged regional leader in providing a full spectrum of commercial real estate services. Services offered include brokerage, appraisal, property management, consulting, and project & construction management services. GVA Kidder Mathews facilitates $2.2 billion in commercial real estate transactions each year, and currently manages a property portfolio encompassing more than 22.6 million square feet.  www.gvakm.com

Nature is the world's foremost weekly scientific journal and is the flagship journal for Nature Publishing Group (NPG). Launched in 1869, its original mission statement still leads the Group as we develop publications, explore opportunities arising from new technology and serve a growing audience of readers.NPG publishes journals and online databases across the life, physical and applied sciences and, most recently, clinical medicine. Content encompasses daily news from award-winning journalists, expert opinion and practical methodology, and more high impact research and reviews than any science publisher. Over 30 journals are published in association with prestigious academic societies. www.nature.com 

VC合作伙伴

DSM creates innovative products and services in Life Sciences and Materials Sciences that contribute to the quality of life.  DSM has annual net sales of EUR 9.3 billion and employs some 23,500 people worldwide. The company is headquartered in the Netherlands, with locations on five continents. DSM is listed on Euronext Amsterdam. More information: www.dsm.com / www.dsm.com.cn

Fidelity Asia Ventures (FAV) is the Asian venture capital arm of FIL Limited, part of the global Fidelity Investments organization. Fidelity Investments is one of the largest mutual fund organizations in the world, managing assets in excess of $1.5 trillion globally.
FAV's mission is to invest in high-quality, high-growth companies broadly in the information technology, healthcare, and consumer sectors in China. FAV has offices in Hong Kong, Beijing, and Shanghai, and a successful track record of investing in leading companies within their respective industries. Current investments and recent exits include: Alibaba (HKSE: 1688), AsiaInfo (NASDAQ: ASIA), Wuxi PharmaTech (NYSE: WX), Hurray! (NASDAQ: HRAY), Linktone (NASDAQ: LTON), Xunlei, and iSoftstone etc. For more information, please visit:  www.fidelityasiaventures.com

HBM BioMed China is a specialized venture capital organization dedicated exclusively to life sciences in China. Our main investments will be in China, or in multinational companies that have major operations within China. HBM BioMed China Limited is domiciled in the Cayman Islands and is advised by HBM BioMed China Partners, Hong Kong. HBM BioVentures, an internationally renowned Swiss life science focused holding company is the major shareholder of HBM Biomed China.
With all management team members based in mainland China, we are one of the first foreign venture capital organizations committed to take root in China’s Healthcare Industry. HBM BioMed China strives to generate long-term capital gains via investments in private companies within its target sectors human medicine, biotechnology and medical technology, as well as related industries. HBM BioMed China inherited the successful management model of HBM BioVentures in the hope of promoting China’s Healthcare Industry under its proactive collaboration and cooperation with other Chinese investment companies and cooperation with other Chinese investment companies and institutions. www.hbmbiomedchina.com

Lilly Ventures is the venture capital arm of Eli Lilly and Company, a leading innovation-driven pharmaceutical company. Our primary goal is to facilitate the success of companies in our areas of focus through early to expansion stage investments and value-adding resources.
Lilly Ventures currently has $175 million under management and focuses on three major areas of interest.
Biotechnology: targeting investments in biotechnology companies that leverage proprietary drug discovery or development technologies to build a robust pipeline.
Medical Technology: targeting investments in companies focusing on the convergence of pharmaceuticals, devices or diagnostics.
Healthcare IT: targeting investments in start-up companies with innovative network technologies that promise to have a transformational impact on the current pharmaceutical business model.
Our investment approach centers on working with superior management teams to help them realize the financial potential of their ideas. Accordingly, we provide both financial and intellectual resources to accelerate the management teams’ path to success. Our sister fund, Lilly Asian Ventures, was established in 2007 with a geographic focus on the emerging life science businesses of east and south Asia, particularly China and India. www.lilly.com

Morningside is a diversified investment group founded in 1986 by the Chan family of Hong Kong. The Chan family founded the Hang Lung Group in Hong Kong in 1960. Morningside engaged primarily in private equity and venture capital investments. The group has investments in North America, Europe, across Asia-Pacific, and since 1992, in Mainland China. Morningside was one of the earliest institutional investors in China's internet industry and in recent years has been a leader in China's emerging biotechnology sector. In China's media sector, Morningside has been active in both outdoor and print media.

www.morningside.com.cn

Mustang Ventures is a China-focused venture firm investing in early stage companies that leverage China’s large pool of intellectual talent, burgeoning domestic market, attractive cost structure, and / or proven export capability. Our team combines local investment experience, senior operating leadership and a global network that we leverage to help guide strong entrepreneurs to market success. Mustang’s partners bring together more than 40 years of operating experience and 10 years of investing experience. Our investing team is led by Rob McCormack, who has completed more than 25 investments in private companies while at Trident Capital and Integral Capital Partners, and our operating team by Leonard Liu, who brings more than 30 years experience in the IT industry, building teams and scaling operations at IBM, Acer, Cadence Design Systems, Walker Interactive Systems, ASE and Augmentum – three of which he grew to sales greater than $1 billion. Mustang has a strategic relationship with Trident Capital of Palo Alto, California. We work closely with our portfolio companies in all aspects of company building. From conceptualization of an idea to building a large and profitable business, we rely on our operational and investment expertise to work with entrepreneurs in building world class organizations.

www.mustangvc.com

OrbiMed is the world’s largest healthcare and life sciences-dedicated investment firm, with approximately $5 billion in assets under management. Since inception of its private equity investment activities in 1993, OrbiMed has successfully invested in over 100 private companies across a wide range of therapeutic categories and stages of development. OrbiMed’s investment team includes over 30 experienced professionals with backgrounds in science, medicine, industry, finance and law. OrbiMed launched the first pan-Asia healthcare and life sciences-dedicated venture capital fund in 2008, with close to $200 million in commitments. OrbiMed maintains offices in New York City, Shanghai, Mumbai and San Francisco. www.OrbiMed.com

In Chinese, “Qiming” literally means starting point and light, purporting the beginning of a new day. Headquartered in Shanghai, Qiming Ventures is dedicated to become a leading venture capital enterprise, devoting to the risk investment to Chinese scientific fields along with its American Ignition Partners. Currently, Qiming Ventures has over $500 million under management; together with its affiliate Ignition Partners, they manage more than $2.5 billion venture capital funds globally. Investment team of Qiming Ventures has rich expertise, enterprise operation practices and investment management experience at home and abroad; Qiming Ventures provides finance to experienced entrepreneurs and businesses with stable profit models, hoping to assist Chinese entrepreneurs to create enterprises with business volumes of billion US $.
Qiming Ventures is active to invest in the following sectors:

• HealthCare
• Media and Internet
• Information Technology
• Consumer and Retail
• Clean Energy

www.qimingventures.com

SUMA VENTURES is a cross border China/US venture capital firm committed to the high-tech and life science industry. Due to its entrepreneurial roots, Suma often plays an active role in the founding and value creation of its portfolio companies. Some of the companies Suma has invested in include a number of platform companies in the areas of contract research organization (CRO), contract manufacturing organizations (CMO), antibody and small molecule anti-cancer drug development technology companies. Suma’s strengths and investment focus is to bridge the best resources of Silicon Valley and China to build leading world class life science companies in China. This is being done by bringing leading US technology and entrepreneurs to China, supporting them with strategically aligned government and professional capital resources, along with guidance from the most successful Chinese entrepreneurs to mentor and build early and growth stage life science opportunities in China, which are laying the foundation for China to become the #1 life science market in the world.

WI Harper Group works with entrepreneurs who target growth opportunities in Greater China as a key objective for their business. WI Harper pioneered the concept of building a business bridge across the Pacific Ocean for early stage IT and life sciences companies. Since 1996, we have backed over 90 emerging companies in China, Taiwan and the United States, resulting in 15 IPOs and a number of M&A transactions. Our investment professionals in Beijing, San Francisco and Taipei manage over $400M in assets. WI Harper currently manages six funds totaling over US$400 million from its headquarters in San Francisco and branch offices in Beijing, Taipei, and Singapore. WI Harper's portfolio includes over 90 companies in high-growth areas of information technology and life sciences. WI Harper's list of successful portfolio companies currently include examples such as Focus Media (NASDAQ: FMCN), ISSI (NASDAQ: ISSI), iKang, DivX (NASDAQ: DIVX), Commerce One, Bridge Pharmaceutical, Cardiva Medical, PC Home, Kuro, Silicon Motion (NASDAQ: SIMO), Beijing Xinwei, Verisilicon, China Broad Media, MAXTHON, HomeE, Panorama Stock, 3G Portal, Mapbar and Laszlo etc. The firm's previous investments include with companies such as Creative Technology, CommerceOne, Intraware, S3, ISSI and many other public companies.
www.wiharper.com

支持伙伴

Chinese-American BioPharmaceutical Society (CABS) is a not-for-profit, non-political, non-religious professional organization headquartered in San Francisco, California. With the rapid development of bio/pharmaceutical industry in China, more and more people, regardless of their ethnic backgrounds, are looking toward China for business and scientific opportunities. Recognizing this trend, CABS was established not only to educate the public with the progress in biotech and pharmaceutical fields, but also to serve the Bio/Pharmaceutical professionals who are either with Chinese heritage or with professional interests in China. The majority of CABS members are Chinese scientists, entrepreneurs and students/postdocs in biomedical sciences, working in San Francisco Bay Area bio/pharmaceutical industries, universities, and research institutes. The CABS membership is open to the public. www.cabsweb.org/CABSweb/home_page.jsp

 

The Chinese Biopharmaceutical Association (CBA) is a non-profit organization made up of professionals who have an interest in bio-pharmaceutical research and/or technology development. CBA was established in 1995 and its headquarters are located in the State of Maryland, which is adjacent to the U.S. capital city of Washington D.C. The majority of CBA members are Chinese scientists, researchers, or professors. They work in government agencies, universities, research institutes as well as in the biotechnology and pharmaceutical industries. Some are conducting pioneering research with the National Institutes of Health (NIH), whereas others are directly involved in the government regulatory process as officers of the Food and Drug Administration (FDA) or in the field of intellectual property as patent attorneys or as patent examiners with the Patent and Trademark Office (PTO). www.cba-usa.org/cba_home.htm

 

 

ChinaSF is an economic development platform supporting business exchange between China and San Francisco. It is a partnership between the City of San Francisco Mayor's Office and the San Francisco Center for Economic Development. With an office in Shanghai and in San Francisco, it is able to provide bi-lingual cross-border support to Chinese businesses interested in expanding business operations to North America. In particular, it can connect Chinese businesses to necessary professional service resources, business partners and can help navigate government regulations. This initiative builds on the already strong cultural exchange between San Francisco and China by providing a systematic support for strengthening business and economic relations.www.sfced.org/international/chinasf

 

 

Guangzhou Economic & Technological Development District（GETDD）was established in December 1984 with the approval of the State Council and covers an area of over 60.6 km2. Since its establishment, GETDD has attracted many hi-tech and biotech companies to the area, building a modern industry base in the development district and creating an environment attractive to early stage life science companies as well as established companies. GETDD is considered to be one of the leading state development districts in China. eng.luogang.gov.cn

 

 

Guangzhou Biotechnology Center (namely Biomedical work group of Guangzhou Municipal Government) under the jurisdiction of the Biotechnology Steering Group and the Sciences &Technology Bureau of Guangzhou Municipal Government is a service agency specializing in biotechnology and medicine industry. Its key missions are to develop the biotechnology and medicine industry of Guangzhou and to accelerate the transfer of S&T achievements and parallel cooperation and exchange. www.gzbio.net

 

Hong Kong Science and Technology Parks Corporation (HKSTP) is a statutory body set up by the Government of the Hong Kong SAR to promote and facilitate the transformation of Hong Kong into Asia’s hub for technology innovation. The Corporation supports a number of technology industries engaging in cutting-edge research and development, including the Life Science and Biotechnology industries, and offers a comprehensive range of facilities and services to address the needs of companies at various stages of development. www.hkstp.org

The Shanghai Pharma Engine has been largely responsible for the launch of the early stage biotech industry in Shanghai. They operate an incubator in the Zhangjiang Hi-Tech Park located next to ChinaBio's offices with 45 biotech startups housed in two buildings, and they are adding facilities for an additional 100 companies in the next year. The ChinaBio? Accelerator recently signed a collaboration agreement with the Pharma Engine where ChinaBio? will identify co-investment opportunities in the Park and Pudong New Area. www.pharma-engine.com/EN/

 

Sino-American Biomedical and Pharmaceutical Professionals Association (SABPA) is a 501(C) (3) nonprofit organization founded in early 2002 by professionals and scholars from local Chinese community in San Diego. We invite all scholars, students and professionals with any origin who are working in, engaged in, or interested in the biotech and pharmaceutical industry to join us as members of SABPA. www.sabpa.org/web/index.php

 

The Sino-American Pharmaceutical Professionals Association (SAPA) was founded in 1993 as a non-profit organization with its headquarters in the Greater New York area (NJ/NY/CT). SAPA has grown rapidly to become one of the most active and well-recognized professional organizations in the United States with over 4000 members. SAPA's missions are to facilitate the advancement of pharmaceutical science and biotechnology, to contribute to public health education, to foster personal and professional career development, and to promote scientific exchange and business cooperation between the USA and China. In addition to the Greater New York area, SAPA has established regional chapters in New England (SAPA-NE), Greater Philadelphia (SAPA-GP) and West Coast (SAPA-WEST), as well as Shanghai Club (SAPA-Shanghai). www.sapaweb.org

 

 

Shanghai Pudong Bio Industry Association (SPBIA), officially founded on September 12, 2002, is serving as a social group registered in Pudong New Area. According to “The Registration and Management Principal for Social Groups”, it will recruit voluntary members from enterprises, research institutes, colleges of medicine and individuals who works in bio-pharmaceutical industry. It is also the registered legal entity approved by the Bureau of Civil Administration of Pudong New Area. Its superior management unit is the Scientific and Technological Association of Pudong New Area. www.spbia.cn/english/index.asp

TJAB experiment “Tianjin Binhai New Area Model” in operation which is “organized by government, driven by market; owned by state, managed by enterprises; setting-up for broad collabration, opening-up to all friends; international cooperation and multilateral acknowledgement”. TJAB aims to serve as a magnet for talents, a bridge for international cooperation, and a role model for bio-medical technology R&D in China, and to become a leading innovation source of bio-medical industry for Tianjin and even the Beijing-Tianjin-Hebei region. It will become an internationally renowned bio-medical innovation base in China, and enable giant leaps in the development of bio-medical industry in the Beijing-Tianjin-Hebei region. www.tjab.org/en/

The development operations, integration services and technology investment work of the base are committed by Shanghai Zhangjiang Bio-Pharmaceutical Base Development Co., Ltd. After more than 10 years of development, as the core district of Shanghai National Bio-Industry Base, National Science and Technology Commercial Innovation Base and National Pharmaceutical Export Base, it has gathered more than 400 companies, research institutes and related service institutions both home and abroad in the field of life science, and formed a comprehensive bio-pharmaceutical innovation system and industrial clusters. In the domestic bio-pharmaceutical field, it’s one of those most concentrated research and development institutions with the most powerful innovation technology and the most prominent invention of new drugs.  www.zjbpb.com/web/index.asp

媒体伙伴

BioonGroup, established since 2001 in China, as the leading service organization, provides latest news, instruments and reagents information, professional consulting and marketing survey and analysis based on life sciences and medicine. The divisions of BioonGroup include 6 websites and 3 subbrands including BIOON, MedSci and BioInsight. Our mission is that building a rapid and convenient platform to link supplies to pharmaceutical, biotech, and research customers. Meanwhile, over 1.5 million registered and permission users’ database could help to delivery enterprises news and products information to them via Electronic Direct Mail (EDM) or Direct Mail (DM). All these work aim to accelerate China biotech industry development. Currently, the page views of our websites are more than 2 million each day. Most of who possess Master or Doctoral degrees and over 70% of the registered members come from the top 50 Chinese universities and institutes.www.bioon.com

China Daily is one of the most authoritative providers of news and views in China. The paper has an average daily circulation of more than 300,000 in about 150 countries and regions. Two-thirds of China Daily’s worldwide readers are government officials, think-tanks and decision makers from multinational corporations. China Daily group has 11 English publications and one of the country’s top news internet portals. The website is one of the biggest English portals in Asia with more than 12 million daily hits, two-thirds of which are from overseas. China Daily’s Hong Kong edition is the only national publication in Hong Kong. 21st Century Weekly is the most-read English education weekly in China. A strategic cooperation agreement to open up China’s English educational market has been signed by China Daily and Scholastic Inc., the world’s largest publisher and distributor of children’s books. www.chinadaily.com.cn

 

 

CRO Asia © is a premium online media platform targeting pharmaceutical outsourcing industry namely contract research and manufacturing organizations based in Asia-Pacific regions. Our objective is to forge potential collaborations and strategic partnerships by using our unique marketing tools and quality communication services. For more information, please visit us at

www.croasia.net

 

VentureWire Lifescience is the venture industry’s premier source for comprehensive, accurate, daily intelligence on how health care-focused venture firms and their portfolio companies are gaining traction, creating value and finding exits in today’s complicated marketplace. Leveraging the global reporting acumen of Dow Jones, this extraordinary e-newsletter delivers right to your inbox every business morning:

• Breaking News - Comprehensive news and analysis of pipeline developments, FDA rulings, licensing and partnership agreements, open and closed deals, and more.
• Strategic Insights - FIRST notice of current deals, future financing plans, burn rates, valuations, forward market trends … days, even weeks, ahead of other sources (yes, even the free ones)!
• In-Depth Trend Analysis - Exclusive reporting about what’s really happening - and why - with venture capital fund-raising, investment, liquidity, deal terms, compensation, and other key areas.
• Personnel Updates – Advance warning of key executive moves, board-level changes, CEO hirings and firings, new partners and available positions.

www.venturecapital.dowjones.com

《医药经理人》（月刊）2008年12月正式创刊，以资深医药传媒人为基础团队，定位为“医药行 业的新闻与资源中心”，核心读者群为医药企业经营者、投资 者、医药行业监管与服务机构。主办单位是中国医药企业管理协会和卓信医学传媒集团。在内容制作上，把求实放在第一位，打通整个产业链条，挖掘药企经营者的 经验与焦虑，战略与执行，成长与使命。形成中国医药行业最丰富的企业成长案例库。将国际视野和本土智慧有机结合，开放而聚焦，把对医药产业最丰富和深刻的 理解带给读者，建立医药产业媒体新话语。把医药研发新产品、生产流通、产业监管与服务机构、资本等资讯第一时间放到行业高端媒体平台，形成信息对称，发现 价值，共同成长。我们的愿景是每一位医药从业者手上都有一本《医药经理人》，我们现在要做的是每一期杂志都能给读者创造出一种兴奋感。www.he-cn.com

 

Interfax China is a member of the Interfax International Information Group. Interfax Group provides news and other information products that are essential for decision-makers in politics and business. Since early 1990s, Interfax has been the main provider of up-to-date news from Russia and countries of the former Soviet Union. We are the most frequently quoted source of information on the region. Over the past few years, Interfax has also become a leading provider of political and business news from China and emerging markets of Central Europe. www.interfax.cn

 

PharmAsiaNews.com is an online portal providing news and analysis on regulatory, legal and financial developments affecting pharmaceutical, biologics and medical device manufacturers doing business in China, India, Japan and other nations of the Pacific Rim. PharmAsiaNews.com leverages the editorial excellence of "The Pink Sheet" -- the leading information source for the U.S. pharmaceutical industry since 1939. Subscribers get original on-the-ground reporting from news bureaus across Asia, guest columns, exclusive interviews, news summaries, English translation summaries of Chinese- and Japanese-language news, and aggregated content from around the globe. Free 30-day trial.

www.PharmAsiaNews.com

 

 

Pharma Connections Worldwide^® is the leading professional business networking website focused in the Pharmaceutical, Biotechnology and Life Sciences research industry. Our goal is to provide a conduit for delivery of premiere content coupled with the right clientele in order to facilitate business development opportunities among industry professionals responsible for making key decisions in a global marketplace. www.pharmaconnections.com